Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for MYGN
+0.15 (0.43%)
After Hours: 35.00 +0.01 (0.02%)
May 25, 4:52PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 34.75 - 35.18
52 week 30.30 - 46.24
Open 34.85
Vol / Avg. 0.00/873,043.00
Mkt cap 2.50B
P/E 23.63
Div/yield     -
EPS 1.48
Shares 70.30M
Beta 0.57
Inst. own 117%
Aug 9, 2016
Q4 2016 Myriad Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 11, 2016
Myriad Genetics Inc at Bank of America Merrill Lynch Health Care Conference
May 3, 2016
Q3 2016 Myriad Genetics Inc Earnings Call
May 3, 2016
Q3 2016 Myriad Genetics Inc Earnings Release
Mar 15, 2016
Myriad Genetics Inc at Barclays Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 17.11% 11.09%
Operating margin 22.36% 18.56%
EBITD margin - 22.02%
Return on average assets 15.03% 10.09%
Return on average equity 16.97% 11.61%
Employees 2,038 -
CDP Score - -


320 S Wakara Way
SALT LAKE CITY, UT 84108-1214
United States - Map
+1-302-6587581 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing, or assess a patient's risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Mark C. Capone President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 83
Bio & Compensation  - Reuters
R. Bryan Riggsbee CPA Chief Financial Officer, Treasurer
Age: 45
Bio & Compensation  - Reuters
Alexander Ford Corporate Executive
Age: 48
Bio & Compensation  - Reuters
Ralph L. McDade Ph.D. President of Myriad RBM, Inc
Age: 61
Bio & Compensation  - Reuters
Bernard F. Tobin President of Crescendo Bioscience, Inc
Age: 58
Bio & Compensation  - Reuters
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 59
Bio & Compensation  - Reuters
Jerry S. Lanchbury Ph.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters